Investing.com – U.S. stocks were mixed after the close on Monday, as gains in the Industrials, Telecoms and Financials sectors led shares higher while losses in the Utilities, Oil...
Castle Biosciences (CSTL): Q3 GAAP EPS of $0.05 beats by $0.35. Revenue of $14.77M (+298.1% Y/Y) beats by $5.32M. Press Release
Nektar Therapeutics shares made a handy gain on Monday after the firm announced updated results from its first-in-human Phase 1a study of NKTR-358 for the treatment of autoimmune...
Nektar Therapeutics (NASDAQ:NKTR) reported a loss of 56 cents per share for the third quarter of 2019, narrower than the Zacks Consensus Estimate of a loss of 73 cents but flat...
|Type||5 mins||15 mins||Hourly||Daily||Monthly|
|Moving Averages||Sell||Strong Sell||Sell||Sell||Strong Sell|
|Technical Indicators||Strong Sell||Strong Sell||Strong Sell||Strong Buy||Strong Sell|
|Summary||Strong Sell||Strong Sell||Strong Sell||Neutral||Strong Sell|
Filter Table By:
|Pattern||Timeframe||Reliability||Candles Ago||Candle Time|
|Three Outside Down||30||Current|
|Belt Hold Bearish||1H||Current|
|Three Black Crows||1D||1||Nov 13, 2019|
|Engulfing Bearish||30||1||Nov 14, 2019 03:00PM|
|Three Black Crows||15||1||Nov 14, 2019 03:30PM|
|Agnico Eagle Mines||59.220||59.644||58.820||+0.250||+0.42%||697.03K||15:59:59|
Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company's research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates. These drug candidates utilize its polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Its programs include Immuno-oncology (I-O), Immunology, Pain-NKTR-181 and Oncology-ONZEALD. It is developing medicines designed to directly or indirectly modulate the activity of key immune cells, such as cytotoxic T cells and Natural Killer (NK) cells, to increase their numbers and improve their function to recognize and attack cancer cells.Read More
|U.S. Commodity Futures Trading Commission (United States), Securities and Exchange Commission (United States)||$0||Start Trading|
|National Futures Association (United States), Financial Industry Regulatory Authority (United States), Securities Investor Protection Corporation (United States)||$500||Start Trading|
|Securities Investor Protection Corporation (United States)||$0||Start Trading|
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.